Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.75 |
| ▸ | CA2 | P00918 | 11/20 | 0.75 |
| ▸ | CA9 | Q16790 | 11/20 | 0.75 |
| ▸ | CA12 | O43570 | 10/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 2/20 | 0.51 |
| ▸ | CA5A | P35218 | 2/20 | 0.51 |
| ▸ | CA7 | P43166 | 2/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.51 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | MMP8 | P22894 | 1/20 | 0.50 |
| ▸ | MMP13 | P45452 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16894131 | 0.83 | ALDH1A1 (0.71) | CA1CA2CA9CA12MMP1 | |
| SCHEMBL19011453 | 0.81 | ALDH1A1 (0.61) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL3013616 | 0.81 | CA1 (0.51) | CA1CA2CA9CA12MMP1 | |
| SCHEMBL4025712 | 0.81 | CA1 (0.56) | CA1CA2CA9CA12MMP1 | |
| SCHEMBL12362794 | 0.81 | ALDH1A1 (0.54) | CA1CA2CA9CA12MMP1 | |
| SCHEMBL3528919 | 0.81 | CYP2C19 (0.57) | CA1CA2CA9CA12MMP1 | |
| SCHEMBL5032650 | 0.80 | CYP19A1 (0.60) | CA1CA2CA9CA12CA4 | |
| SCHEMBL22501722 | 0.79 | CA1 (0.71) | CA1CA2CA9CA12CYP3A4 | |
| SCHEMBL1018953 | 0.77 | MEP1B (0.58) | CA1CA2CA9CA12CA6 | |
| SCHEMBL30208033 | 0.77 | ALDH1A1 (0.63) | CA1CA2CA9CA12MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303496-B9 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-03-19 | — | — | EP | disclosed |
| EP-1303496-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-09-12 | — | — | EP | disclosed |
| EP-1406876-B1 | 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2006-12-27 | — | — | EP | disclosed |
| US-6939872-B2 | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-20040198757-A1 | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors | ASTRAZENECA AB (SE) | 2004-10-07 | — | — | US | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1406876-A1 | 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | Astrazeneca AB (SE) | 2004-04-14 | — | — | EP | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002096887-A1 | 2-ANILINO-PYRIMIDINE DERIVATIVES AS CYCLIN DEPENDENT KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198757-A1 | 2-anilino-pyrimidine derivatives as cyclin dependent kinase inhibitors | CCNT1, CCNI, CDK2 | CA1 2019/4885CA2 1307/4885CA9 2990/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | CA1 2976/4885CA2 2384/4885CA9 2902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.